These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32480059)

  • 1. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
    White HD; Stewart RAH; Dalby AJ; Stebbins A; Cannon CP; Budaj A; Linhart A; Pais P; Diaz R; Steg PG; Krug-Gourley S; Granger CB; Hochman JS; Koenig W; Harrington RA; Held C; Wallentin L;
    Am Heart J; 2020 Jul; 225():97-107. PubMed ID: 32480059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
    Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
    Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
    Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
    JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
    Morgan CL; Durand A; McCormack T; Hughes E; Berni TR; Lahoz R
    BMJ Open; 2023 Nov; 13(11):e064541. PubMed ID: 38030254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    De Ferrari GM; Stevens SR; Ambrosio G; Leonardi S; Armstrong PW; Green JB; Wamil M; Holman RR; Peterson ED;
    Am Heart J; 2020 Feb; 220():82-88. PubMed ID: 31790905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
    Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
    JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol ≤ 50 mg/dl.
    Piao ZH; Jin L; Kim JH; Ahn Y; Kim YJ; Cho MC; Kim CJ; Kim HS; Liu B; Jeong MH;
    Am J Cardiol; 2017 Jul; 120(2):174-180. PubMed ID: 28532771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
    Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M;
    Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.
    Zhong Z; Hou J; Zhang Q; Zhong W; Li B; Li C; Liu Z; Yang M; Zhao P
    Lipids Health Dis; 2019 Feb; 18(1):40. PubMed ID: 30711009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
    Giugliano RP; Wiviott SD; Blazing MA; De Ferrari GM; Park JG; Murphy SA; White JA; Tershakovec AM; Cannon CP; Braunwald E
    JAMA Cardiol; 2017 May; 2(5):547-555. PubMed ID: 28291866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
    Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
    J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial.
    Ali MK; Chwastiak L; Poongothai S; Emmert-Fees KMF; Patel SA; Anjana RM; Sagar R; Shankar R; Sridhar GR; Kosuri M; Sosale AR; Sosale B; Rao D; Tandon N; Narayan KMV; Mohan V;
    JAMA; 2020 Aug; 324(7):651-662. PubMed ID: 32809002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained low-density lipoprotein-cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting.
    Sánchez-Bacaicoa C; Galán J; Guijarro C; Rico-Martín S; Monreal M; Calderón-García JF; Aguilar-Cortés E; Sánchez Muñoz-Torrero JF;
    Eur J Clin Invest; 2022 May; 52(5):e13732. PubMed ID: 34908162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
    Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
    Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
    Bangalore S; Breazna A; DeMicco DA; Wun CC; Messerli FH;
    J Am Coll Cardiol; 2015 Apr; 65(15):1539-48. PubMed ID: 25881936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.